• 1
    Zhu M, Chang Q, Wong LK, Chong FS, Li RC. Triterpene antioxidants from Ganoderma lucidum. Phytother Res 1999; 13: 52931.
  • 2
    Wachtel-Galor S, Tomlinson B, Benzie IF. Ganoderma lucidum (“Lingzhi”), a Chinese medicinal mushroom: biomarker responses in a controlled human supplementation study. Br J Nutr 2004; 91: 2639.
  • 3
    Wachtel-Galor S, Szeto YT, Tomlinson B, Benzie IF. Ganoderma lucidum (‘Lingzhi’): acute and short-term biomarker response to supplementation. Int J Food Sci Nutr 2004; 55: 7583.
  • 4
    Bao XF, Wang XS, Dong Q, Fang JN, Li XY. Structural features of immunologically active polysaccharides from Ganoderma lucidum. Phytochemistry 2002; 59: 17581.
  • 5
    Kim RS, Kim HW, Kim BK. Suppressive effects of Ganoderma lucidum on proliferation of peripheral blood mononuclear cells. Mol Cells 1997; 7: 527.
  • 6
    Tasaka K, Akagi M, Miyoshi K, Mio M, Makino T. Anti-allergic constituents in the culture medium of Ganoderma lucidum. I. Inhibitory effect of oleic acid on histamine release. Agents Actions 1988; 23: 1536.
  • 7
    Lei LS, Lin ZB. Effect of Ganoderma polysaccharides on T cell subpopulations and production of interleukin 2 in mixed lymphocyte response. Yao Xue Xue Bao 1992; 27: 3315.
  • 8
    Haak-Frendscho M, Kino K, Sone T, Jardieu P. Ling Zhi-8: a novel T cell mitogen induces cytokine production and upregulation of ICAM-1 expression. Cell Immunol 1993; 150: 10113.
  • 9
    Lai KN, Chan LY, Tang SC, Leung JC. Ganoderma extract prevents albumin-induced oxidative damage and chemokines synthesis in cultured human proximal tubular epithelial cells. Nephrol Dial Transplant 2006; 21: 118897.
  • 10
    Hu H, Ahn NS, Yang X, Lee YS, Kang KS. Ganoderma lucidum extract induces cell cycle arrest and apoptosis in MCF-7 human breast cancer cell. Int J Cancer 2002; 102: 2503.
  • 11
    Sliva D, Sedlak M, Slivova V, Valachovicova T, Lloyd FP, Ho NW. Biologic activity of spores and dried powder from Ganoderma lucidum for the inhibition of highly invasive human breast and prostate cancer cells. J Altern Complement Med 2003; 9: 4917.
  • 12
    Wang SY, Hsu ML, Hsu HC, Tzeng CH, Lee SS, Shiao MS, et al. The anti-tumor effect of Ganoderma lucidum is mediated by cytokines released from activated macrophages and T lymphocytes. Int J Cancer 1997; 70: 699705.
  • 13
    Yuen JW, Gohel MD. Anticancer effects of Ganoderma lucidum: a review of scientific evidence. Nutr Cancer 2005; 53: 117.
  • 14
    Bomalaski J, Clark M. Phospholipase A2 and arthritis. Arthritis Rheum 1993; 36: 1908.
  • 15
    Bradley JD, Dmitrienko AA, Kivitz AJ, Gluck OS, Weaver AL, Wiesenhutter C, et al. A randomized, double-blinded, placebo-controlled trial of LY333013, a selective inhibitor of group II secretory phospholipase A2, in the treatment of rheumatoid arthritis. J Rheumatol 2005; 32: 41723.
  • 16
    Garcia Pastor P, de Rosa S, de Giulio A, Paya M, Alcaraz M. Modulation of acute and chronic inflammatory processes by cacospongionolide B, a novel inhibitor of human synovial phospholipase A2. Br J Pharmacol 1999; 126: 30111.
  • 17
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 31524.
  • 18
    Koh ET, Seow A, Pong LY, Koh WH, Chan L, Howe HS, et al. Cross cultural adaptation and validation of the Chinese Health Assessment Questionnaire for use in rheumatoid arthritis. J Rheumatol 1998; 25: 17058.
  • 19
    Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993; 36: 72940.
  • 20
    Benzie I, Strain JJ. Ferric reducing/antioxidant power assay: direct measure of total antioxidant activity of biological fluids and modified version for simultaneous measurement of total antioxidant power and ascorbic acid concentration. Methods Enzymol 1999; 299: 1527.
  • 21
    Benzie I, Strain J. The ferric reducing ability of plasma (FRAP) as a measure of “antioxidant power”: the FRAP assay. Anal Biochem 1996; 239: 706.
  • 22
    Tang NL, Chan PK, Wong CK, To KF, Wu AK, Sung YM, et al. Early enhanced expression of interferon-inducible protein-10 (CXCL-10) and other chemokines predicts adverse outcome in severe acute respiratory syndrome. Clin Chem 2005; 51: 233340.
  • 23
    Compiled by the State Pharmacopoeia Commission of P. R. China. Parmacopoeia of the People's Republic of China. Beijing; Chemical Industry Press: 2000.
  • 24
    Chiu SW, Wang ZM, Leung TM, Moore D. Nutritional value of Ganoderma extract and assessment of its genotoxicity and antigenotoxicity using comet assays of mouse lymphocytes. Food Chem Toxicol 2000; 38: 1738.
  • 25
    Chang R. Effective dose of Ganoderma in humans. In: Buchanan PK, Hseu RS, Moncalvo JM, editors. Proceedings of the Contributed Symposium 59A, B of the 5th International Mycological Congress. Taipei; 1994. p. 10113.
  • 26
    Pruzanski W, Vadas P, Stefanski E, Urowitz M. Phospholipase A2 activity in sera and synovial fluids in rheumatoid arthritis and osteoarthritis: its possible role as a proinflammatory enzyme. J Rheumatol 1985; 12: 2116.
  • 27
    Wong CK, Ho CY, Li EK, Tam LS, Lam CW. Elevated production of interleukin-18 is associated with renal disease in patients with systemic lupus erythematosus. Clin Exp Immunol 2002; 130: 34551.
  • 28
    Sato M, Takemura M, Shinohe R, Koishi H, Morita T, Seishima M. Clinical significance of serum IL-18 determination in rheumatoid arthritis. Rinsho Byori 2004; 52: 10914. In Japanese.
  • 29
    Matsumoto K, Kanmatsuse K. Elevated interleukin-18 levels in the urine of nephrotic patients. Nephron 2001; 88: 3349.
  • 30
    Wong CK, Ho CY, Li EK, Lam CW. Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus. Lupus 2000; 9: 58993.
  • 31
    Wong CK, Ho CY, Ko FW, Chan CH, Ho AS, Hui DS, et al. Proinflammatory cytokines (IL-17, IL-6, IL-18 and IL-12) and Th cytokines (IFN-γ, IL-4, IL-10 and IL-13) in patients with allergic asthma. Clin Exp Immunol 2001; 125: 17783.
  • 32
    Hijikata Y, Yamada S. Effect of Ganoderma lucidum on postherpetic neuralgia. Am J Chin Med 1998; 26: 37581.
  • 33
    Hijikata Y, Yasuhara A, Sahashi Y. Effect of an herbal formula containing Ganoderma lucidum on reduction of herpes zoster pain: a pilot clinical trial. Am J Chin Med 2005; 33: 51723.
  • 34
    Kwok Y, Ng KF, Li CC, Lam CC, Man RY. A prospective, randomized, double-blind, placebo-controlled study of the platelet and global hemostatic effects of Ganoderma lucidum (Ling-Zhi) in healthy volunteers. Anesth Analg 2005; 101: 4236.
  • 35
    Tang W, Gao Y, Chen G, Gao H, Dai X, Ye J, et al. A randomized, double-blind and placebo-controlled study of a Ganoderma lucidum polysaccharide extract in neurasthenia. J Med Food 2005; 8: 538.
  • 36
    Xi Bao Y, Kwok Wong C, Kwok Ming Li E, Shan Tam L, Chung Leung P, Bing Yin Y, et al. Immunomodulatory effects of lingzhi and san-miao-san supplementation on patients with rheumatoid arthritis. Immunopharmacol Immunotoxicol 2006; 28: 197200.